Characterization of ventricular tachycardia ablation in end-stage heart failure patients with left ventricular assist device (CHANNELED registry).
Jan-Hendrik van den Bruck,Felix Hohendanner,Emanuel Heil,Karolin Albert,David Duncker,Heidi L. Estner,Thomas Deneke,Abdul Shokor Parwani,Evgenij Potapov,Katharina Seuthe,Jonas Woermann,Arian Sultan,Jan-Hendrik Schipper,Lars Eckardt,Florian Doldi,Patrick Lugenbiel,Helge Servatius,Gregor Thalmann,Tobias Reichlin,Moneeb Khalaph,Denise Guckel,Philipp Sommer,Daniel Steven,Jakob Lüker
DOI: https://doi.org/10.1101/2024.10.30.24316462
2024-11-26
Abstract:Background: Patients with left-ventricular-assist-devices (LVAD) are at high risk for ventricular tachycardia (VT), and data on VT ablation in LVAD patients is scarce. This multicenter registry assessed the mechanism of VT, procedural parameters, and outcome of VT ablation in LVAD patients ( ).
Methods: Data of LVAD patients referred for VT ablation at 9 tertiary care centers were collected retrospectively. Parameters included VT mechanisms, procedural data, VT recurrence, and mortality.
Results: Overall, 69 patients (90% male, mean age 60.7±8.4 years) undergoing 72 catheter ablation procedures were included. Most procedures were conducted after intensification of antiarrhythmic drug (AAD) treatment (18/72; 25%) or after prior combination of 2 AADs (31/72; 43%). Endocardial low voltage areas were detected in all patients. 96 different VTs were targeted. The predominant mechanism was scar-related re-entry (76/96 VTs; 79%) and 19/96 VTs (20%) were related to the LVAD cannula. Non-inducibility of any VT was achieved in 28/72 procedures (39%). No LVAD related complication was observed. The extent of endocardial scar was associated with VT recurrence. Over a median follow-up of 283 days (IQR 70-587 days), 3/69 were lost to follow-up, 10/69 (14%) patients were transplanted, 26/69 (38%) died, and 16/69 (23%) patients were free from VT.
Conclusion: Although often a last resort, VT ablation in LVAD patients is feasible and safe when performed in experienced centers. These patients suffer from a high scar burden, and cardiomyopathy-associated rather than cannula-related scar seems to be the dominant substrate. VT recurrence after ablation is high, despite extensive treatment, and the overall prognosis of these patients is limited.
Cardiovascular Medicine